BioNTech’s May Marathon: A Board Reshuffle, a Founder Exit, and a $17 Billion Bet on Cancer

BioNTech faces pivotal May with Q1 earnings, a governance overhaul for oncology focus, and a stock rebounding 19% from post-founder-exit lows.

The German biotech is barreling toward one of the most consequential stretches in its post-pandemic life. On May 5, BioNTech releases first-quarter earnings; ten days later, shareholders gather virtually for an annual meeting that will reshape the company’s governance. Between those two events sits a stock that has clawed back nearly a fifth of its value since a brutal March selloff, yet still trades well below the $130-plus price targets pinned to it by a majority of analysts.

A Board Built for Oncology

The headline item on the May 15 agenda is a structural overhaul of the supervisory board. The body will expand from six to eight members, with two new specialists in oncology and clinical development slated for election. Three existing members are standing for re-election. The move is a deliberate signal: the company that shot to fame on a COVID vaccine is remaking its leadership in the image of a cancer-fighting enterprise.

Shareholders will also vote on a new authorized capital plan for 2026, worth up to €129.5 million — equivalent to 50% of current share capital — which would replace the expiring 2025 authorization. Other business includes approval of the 2025 compensation report, the reappointment of EY as auditor, and a profit-and-loss transfer agreement with subsidiary BioNTech Discovery GmbH. The retained earnings from 2025, roughly €6.9 billion, are to be carried forward in full.

The Founder Shadow

None of this happens in a vacuum. Co-founders Ugur Sahin and Özlem Türeci announced in March they would leave BioNTech by the end of 2026 to launch a new mRNA venture. The news triggered an 18% single-day plunge on March 10, sending the stock to a 52-week low of €72.50. Since then, the shares have recovered to around €86 — a 19% bounce, but still a long way from the €120-plus levels that prevailed before the exit announcement.

The mood was further soured by the 2026 revenue forecast of €2.0 billion to €2.3 billion, well short of the consensus estimate of roughly €2.75 billion. Add to that the threat of U.S. import tariffs of up to 100% on pharmaceutical ingredients, and the sector-wide headwinds are unmistakable.

Analyst Conviction Holds

Despite the noise, Wall Street remains broadly constructive. HC Wainwright reaffirmed its buy rating and $130 price target in late April. Morgan Stanley edged its target up to $126 with an overweight call. Berenberg stuck with its buy recommendation. Across 13 analysts, the average 12-month price target sits at about $133.

The bull case rests on two pillars: a deep oncology pipeline led by BNT326 for EGFR-positive non-small cell lung cancer, and a cash hoard of roughly €16.7 billion. Leerink Partners is the notable outlier, trimming its target to $94 on weaker prospects for the candidate Gotistobart in a current trial.

A Dense Data Calendar

The company plans to launch six additional Phase 3 studies in 2026 and expects to deliver seven late-stage data packages — the first time it will have readouts across multiple major cancer indications simultaneously. Pumitamig, a bispecific antibody, is already being tested in seven Phase 3 trials.

The May 5 earnings release will be the first hard look at how quickly the new leadership can sustain that clinical momentum. The market will also be watching the burn rate: the transformation from vaccine maker to oncology powerhouse is swallowing enormous sums, and investors want to know how long the €17 billion war chest can fund the research marathon before new cancer products replace the fading COVID revenue.

Behind the scenes, the patent dispute with Moderna continues to simmer. BioNTech and CureVac are seeking royalties on Moderna’s Spikevax vaccine, a legal battle that adds another layer of uncertainty to an already crowded agenda.

For a company navigating a founder departure, a board overhaul, and a make-or-break pipeline push, the next two weeks will provide the clearest signal yet of whether the market’s patience will be rewarded.